Pharmanutra is forecast to grow earnings and revenue by 19.8% and 11.1% per annum respectively. EPS is expected to grow by 19.5% per annum. Return on equity is forecast to be 31.9% in 3 years.
Key information
19.8%
Earnings growth rate
19.49%
EPS growth rate
Personal Products earnings growth
8.0%
Revenue growth rate
11.1%
Future return on equity
31.86%
Analyst coverage
Low
Last updated
12 May 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
BATS-CHIXE:PHNM - Analysts future estimates and past financials data (EUR Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
204
36
33
39
3
12/31/2027
181
31
28
36
3
12/31/2026
155
25
22
29
3
3/31/2026
139
21
16
19
N/A
12/31/2025
132
20
16
20
N/A
9/30/2025
127
17
10
14
N/A
6/30/2025
122
17
8
12
N/A
3/31/2025
119
16
21
25
N/A
12/31/2024
116
17
16
20
N/A
9/30/2024
113
16
19
23
N/A
6/30/2024
108
14
15
20
N/A
3/31/2024
101
11
2
12
N/A
12/31/2023
101
13
-1
12
N/A
9/30/2023
95
12
-5
12
N/A
6/30/2023
93
14
-19
12
N/A
3/31/2023
88
16
-15
14
N/A
12/31/2022
83
15
-9
17
N/A
9/30/2022
79
16
-5
19
N/A
6/30/2022
76
15
10
19
N/A
3/31/2022
73
15
14
20
N/A
12/31/2021
68
14
15
20
N/A
9/30/2021
65
14
13
16
N/A
6/30/2021
60
11
12
15
N/A
3/31/2021
57
14
13
15
N/A
12/31/2020
57
14
10
12
N/A
9/30/2020
58
14
11
11
N/A
6/30/2020
58
14
7
11
N/A
3/31/2020
55
9
4
9
N/A
12/31/2019
54
8
N/A
12
N/A
9/30/2019
49
8
N/A
8
N/A
6/30/2019
50
9
N/A
9
N/A
3/31/2019
48
9
N/A
8
N/A
12/31/2018
47
9
N/A
6
N/A
9/30/2018
44
8
N/A
6
N/A
6/30/2018
41
7
N/A
6
N/A
3/31/2018
40
6
N/A
6
N/A
12/31/2017
38
6
N/A
6
N/A
9/30/2017
37
5
N/A
N/A
N/A
6/30/2017
35
5
N/A
N/A
N/A
3/31/2017
34
4
N/A
N/A
N/A
12/31/2016
33
4
N/A
6
N/A
12/31/2015
26
3
N/A
N/A
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHNM's forecast earnings growth (19.8% per year) is above the savings rate (3.4%).
Earnings vs Market: PHNM's earnings (19.8% per year) are forecast to grow faster than the UK market (11.5% per year).
High Growth Earnings: PHNM's earnings are forecast to grow, but not significantly.
Revenue vs Market: PHNM's revenue (11.1% per year) is forecast to grow faster than the UK market (4.6% per year).
High Growth Revenue: PHNM's revenue (11.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHNM's Return on Equity is forecast to be high in 3 years time (31.9%)
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/18 17:43
End of Day Share Price
2026/05/12 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmanutra S.p.A. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.